EditFrom NeuroLex
Carteolol
| Name: | Carteolol |
| Description: | A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. (PubChem) Pharmacology: Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce. Mechanism of action: The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Antagonists. Anti-Arrhythmia Agents. Antihypertensive Agents. Sympatholytics |
| Synonym(s): | Carteolol HCl, Carteolol Hydrochloride, Carteololum (INN-Latin), Cartrol, Endak Hydrochloride, Ocupress |
| Related to: | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB00521 |
| Id: | CHEBI_3437 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about CarteololRDF feed
| Comment | taken from DrugBank |
| CurationStatus | uncurated + |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB00521 + |
| Definition | A beta-adrenergic antagonist used as an an … A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. (PubChem) Pharmacology: Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce. Mechanism of action: The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. Drug type: Approved. Small Molecule. Drug category: Adrenergic beta-Antagonists. Anti-Arrhythmia Agents. Antihypertensive Agents. Sympatholytics s. Antihypertensive Agents. Sympatholytics |
| Has role | Drug + |
| Id | CHEBI_3437 + |
| Label | Carteolol + |
| ModifiedDate | 16 November 2010 + |
| RelatedTo | Beta-1 adrenergic receptor +, and Beta-2 adrenergic receptor + |
| SuperCategory | Molecule + |
| Synonym | Carteolol HCl +, Carteolol Hydrochloride +, Carteololum (INN-Latin) +, Cartrol +, Endak Hydrochloride +, and Ocupress + |